Immune Age Acceleration Stratifies Survival in Multiple Myeloma Independent of Chronological Age and Clinical Fitness

Chronological age incompletely explains prognostic heterogeneity in multiple myeloma (MM), particularly among younger patients, whose clinical outcomes vary widely. Existing immune aging clocks are predominantly derived from peripheral blood expression data and thus incompletely reflect the aging of the bone marrow (BM) immune microenvironment in MM. To address this limitation, we developed BM immune aging clocks for ten immune and progenitor cell types trained on single-cell RNA-sequencing data from 1,260 healthy peripheral blood and BM samples and calibrated to BM. We then applied these clocks to BM single-cell profiles from 337 newly diagnosed MM patients enrolled in the CoMMpass study to derive a global immune age acceleration score. In patients younger than 70 at diagnosis, accelerated immune aging was independently associated with shorter overall survival (OS; HR = 2.24, p = 0.003) after adjustment for cytogenetic risk, transplant status, triplet therapy administration, chronological age, sex, performance status, and laboratory deficits, whereas chronological age was not predictive. Subsequent analyses identified CD4+ memory T cell aging as the strongest contributor to overall immune age acceleration and its association with shorter OS. Consistent with this, accelerated immune aging was characterized by terminal effector differentiation of memory T cells, TNF-α/NF-κB-mediated inflammation, and increased lymphocyte-driven TNF, CCL3, and IFN-γ signaling. However, inflammatory signaling alone did not account for survival differences. Longitudinally, changes in monocyte immune age acceleration at first progression were associated with shorter subsequent survival (HR = 3.06, p = 0.005). Together, these findings identify BM immune age acceleration as a prognostic measure of biological fitness in MM, distinct from chronological age and clinical frailty.

Authors

Institutions

Publication Details

Journal
bioRxiv (Cold Spring Harbor Laboratory)
Published
2026-11-19
DOI
https://doi.org/10.64898/2026.11.17.767344
Primary Topic
Multiple Myeloma Research and Treatments
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Immune Age Acceleration Stratifies Survival in Multiple Myeloma Independent of Chronological Age and Clinical Fitness

Hearn Jay Cho, Mojtaba Bakhtiari, Lawrence Boise, Ashley Elizabeth Rosko et al.
bioRxiv (Cold Spring Harbor Laboratory)
Multiple Myeloma Research and Treatments
preprint

Immune Age Acceleration Stratifies Survival in Multiple Myeloma Independent of Chronological Age and Clinical Fitness

Hearn Jay Cho, Mojtaba Bakhtiari, Lawrence Boise, Ashley Elizabeth Rosko, Sagar Lonial, Manoj Bhasin, Ravi Vij, Shaji Kunnathu Kumar, Samir Sunil Parekh, Ioannis Vlachos, Linda Banovic Baughn, Mala Shanmugam, Marina Michaud, Megan Moore Weivoda, GEORGE MULLIGAN, Bridget Neary, Sarthak Satpathy, Sacha Gnjatic, Katherine E. Ferguson, Li Ding, David Avigan, Edward Henderson, Ajay Nooka, Chaitanya Acharya, Immune Atlas Network, Denis Ohlstrom, Steven Foltz, William C Pilcher
preprint en

Abstract

Chronological age incompletely explains prognostic heterogeneity in multiple myeloma (MM), particularly among younger patients, whose clinical outcomes vary widely. Existing immune aging clocks are predominantly derived from peripheral blood expression data and thus incompletely reflect the aging of the bone marrow (BM) immune microenvironment in MM. To address this limitation, we developed BM immune aging clocks for ten immune and progenitor cell types trained on single-cell RNA-sequencing data from 1,260 healthy peripheral blood and BM samples and calibrated to BM. We then applied these clocks to BM single-cell profiles from 337 newly diagnosed MM patients enrolled in the CoMMpass study to derive a global immune age acceleration score. In patients younger than 70 at diagnosis, accelerated immune aging was independently associated with shorter overall survival (OS; HR = 2.24, p = 0.003) after adjustment for cytogenetic risk, transplant status, triplet therapy administration, chronological age, sex, performance status, and laboratory deficits, whereas chronological age was not predictive. Subsequent analyses identified CD4+ memory T cell aging as the strongest contributor to overall immune age acceleration and its association with shorter OS. Consistent with this, accelerated immune aging was characterized by terminal effector differentiation of memory T cells, TNF-α/NF-κB-mediated inflammation, and increased lymphocyte-driven TNF, CCL3, and IFN-γ signaling. However, inflammatory signaling alone did not account for survival differences. Longitudinally, changes in monocyte immune age acceleration at first progression were associated with shorter subsequent survival (HR = 3.06, p = 0.005). Together, these findings identify BM immune age acceleration as a prognostic measure of biological fitness in MM, distinct from chronological age and clinical frailty.

bioRxiv (Cold Spring Harbor Laboratory)
Georgia Institute of Technology (US), Beth Israel Deaconess Medical Center (US), Mayo Clinic (US), Emory University (US), Washington University in St. Louis (US), Multiple Myeloma Research Foundation (US), Winship Cancer Institute (US), The Ohio State University (US), Icahn School of Medicine at Mount Sinai (US)
Multiple Myeloma Research and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon